Amitiza (Irritable Bowel Syndrome) Market Forecast and Analysis Report by 2023: Radiant Insights, Inc.
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 02/23/16 -- The Amitiza (Irritable Bowel Syndrome) market had more than USD 655.0 million in 2010 and is anticipated to rise at a CAGR of more than 11.0% over the future to achieve more than USD 1.5 billion by 2018. Irritable Bowel Syndrome is an abdominal disorder connected with distorted function of the bowel. Patients'' life style is affected due to this disorder though Irritable Bowel Syndrome is not a threat to the life. Although it is new, IBS has a large market volume with few pharmacotherapies designated for the disorder treatment and are considered as important unmet requirements.
In the US only, women of age eighteen years and above suffering from IBS-C are specified with Amitiza (lubiprostone). Takeda & Sucampo Pharmaceuticals had developed this product. They got sanction in 2006 in the US for treating chronic idiopathic constipation in people above 18 years of age. Amitiza achieved label extension for the FDA (food and administration) for treating IBS-C in females of age eighteen and above.
The general idea of IBS together with epidemiology, diagnosis, etiology, pathology, symptoms, and treatment strategy in addition to a general idea on the competitive background. The first product which was there for men and women both was Linzess, in 2012 for treating IBS-C. It is suggested as a daily dose of 290 µg orally. Linzess and Amitiza are used for second line and beyond treatment for those who do not react to first-line laxatives and antispasmodics.
The present treatment decisions are based on symptomatic relief offered from a range of IBS manifestations like lower back pain, cancer pain, osteoarthritis pain, fibromyalgia, etc. Hence, the action is focused not on complete cure of illness, and is therefore reasonably successful. The IBS market is divided as per the habit of predominant bowel like constipation predominant, diarrhoea predominant, and an alternating form. The division is owing to product difference in the market accepted with different sub-types.
With respect to these facts, a large unmet requirement occurs for IBS market in each types and sub-types which require original products with better safety efficient profile in comparison to the present products. Hence huge opportunity is there for applications which are new for the market entry with the product contributions competing with the sub-type especial drugs marketed having more effectiveness and protection profiles.
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets.
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.02.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 1417022
Anzahl Zeichen: 3855
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 105 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Amitiza (Irritable Bowel Syndrome) Market Forecast and Analysis Report by 2023: Radiant Insights, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Radiant Insights, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
